New definitions for “significant safety issues” and the introduction of an “other safety issues” category are among the changes that New Zealand’s Medsafe has made in the latest iteration of its pharmacovigilance guideline.
The revised guideline, which is replacing its predecessor that was published in 2020, had been issued for consultation late...




